Dec 1 2014

Americord Funds Trial: Hematological Malignancies

Posted by admin

Americord Funds Clinical Trial Investigating Umbilical Cord Blood Transplantation in Patients with Hematological Malignancies

Funds Will Support Research Into Safety and Efficacy of Genetically Unmatched Cord Blood Stem Cell Transplantations Using a Myeloablative Preparative Regimen.

New York – December 1, 2014 – Americord announced today that it has provided funding to St. Jude’s Children’s Research Hospital, a research and treatment facility for catastrophic diseases in children, primarily pediatric cancers. A myeloablative preparative regimen, a process of preparing the bodies cells for a transplant, is being researched in the hopes that it will increase the chances that an unrelated stem cell transplant will be accepted by the patient’s body.

Americord’s donation of funds is part of the company’s Corporate Giving Program, which was established to support research focused on the therapeutic uses of stem cells from umbilical cord blood, cord tissue, and placenta tissue.

“Americord is committed to supporting the advancement of stem cell technologies that can help treat a range diseases and conditions,” said Americord CEO Martin Smithmyer. “We are excited about St. Jude’s clinical trial and hopeful that it will lead to advances in the treatment of hematological malignancies.”

St. Jude’s study began in March 2011 and is anticipated to be complete by June 2020. It is registered with in accordance with best practices and requirements of the U.S. Food and Drug Administration.

For more information about the clinical trial:

< Back to Blog
Category: Press